Background The aims of this study were to investigate the motives for refusing or attending population-based screening for prostate cancer, in relation to various background characteristics.
Introduction
The motives for men refusing or attending prostate cancer screening are largely unknown. Published results are based on telephone surveys of the general public, or focus only on men who actually participated in the screening but ignore those who refused. 1±4 More insight into the motives for refusing or attending, also in relation to background characteristics, is needed to tailor the invitation and screening procedures. From a health promotional point of view it is important to know on what grounds decisions to participate, or not, are made. In particular, the presence or absence of urological complaints is of interest. This information may contribute to the discussion on the advantageous and disadvantageous public health effects of this still experimental cancer screening programme.
The European Randomized Study of Screening for Prostate Cancer (ERSPC), initiated in 1991, is a population-based study comprising randomization into a screening and a control group. 5±7 The screening group receives a prostate speci®c antigen (PSA) determination, digital rectal examination (DRE), transrectal ultrasound (TRUS) and biopsies on indication. The control group receives no screening. Besides estimating changes in prostate cancer, mortality being the main outcome measure, side studies within ERSPC address issues such as attendance, satisfaction with screening procedures, ef®cacy of screening tests, costs and the impact of screening on healthrelated quality of life at a population level.
In this paper we report on the motives for refusing or attending the screening, in relation to various background characteristics. The study was conducted alongside the sixth ERSPC programme, in 1995±1996. In both refusers and attenders we addressed motives, knowledge of prostate cancer, attitudes towards screening, sociodemographic characteristics, and urological complaints by self-completed questionnaires. Earlier we conducted a similar study. 8 However, the latter study addressed the ®rst pilot of ERSPC (in 1992±1993), whereas in the present study (in 1995±1996) ERSPC has been operational for several years. Secondly, the screening policy has been changed. In 1992±1993 a pre-screening with PSA for both control and screening group was performed (for which both groups had to visit the screening centre), whereas in the present study the screening policy comprised complete randomization. Finally, in the present paper we focus more on differences in knowledge about prostate cancer and attitudes towards screening, and in addition we provide data on urological complaints in relation to (non) attendance.
Methods

ERSPC trial
The outline of the ERSPC trial has been described elsewhere. 6, 7 Men of Dutch nationality aged 55±75 years, in the Rotterdam population registry (coverage 100 per cent), received an invitation letter together with an information lea¯et. No reminder was sent. The information material provided information about the design and purpose of the study, as well as the screening procedures. After written informed consent was obtained, randomization was carried out by mail. That is, men who had given informed consent either received a letter stating that they were part of the control group, or a letter (and a questionnaire, see below) stating that they were part of the screening group. In the latter case they were invited to make an appointment for the screening. The screening group received a prostate speci®c antigen (PSA) determination, digital rectal examination (DRE), transrectal ultrasound (TRUS) and biopsies on indication. 9 Biopsies were taken with a PSA value above 4 ng/ml, or suspicion after DRE (induration) or TRUS (hypoechogenic lesion of any size). All tests were performed at the University Hospital Dijkzigt, Rotterdam.
The outcome of the screening was reported to the participant and his general practitioner immediately after the investigations, except if biopsies were taken. Then an additional visit was scheduled to explain the result of the biopsies. After negative tests (no cancer found), a rescreening was offered for 4 years later. If prostate cancer was detected, the patient was referred to his general practitioner to co-ordinate the urological work-up, as required by the Dutch health care system.
From the control group follow-up data are collected on prostate cancer incidence and mortality, by making use of the regional cancer registry (Comprehensive Cancer Centre, South-West Netherlands). Other relevant data are collected as well, for example, on screening contamination (screening in the control group, outside the context of the ERSPC). The Medical Ethical Committee of the University Hospital Rotterdam approved this study.
Design of the evaluation
A questionnaire with two reminders after 2 and 4 weeks was mailed to a random sample of 500 refusers (no written informed consent), during the ®rst two quarters of 1996. For 626 consecutive men willing to participate and randomized to the screening group, a similar questionnaire was sent before the screening during the last quarter of 1995 and the ®rst two quarters of 1996.
The questionnaires were compiled from existing questions used by the National Central Bureau of Statistics, general health surveys of public health services, evaluation studies of cervical and breast cancer screening, and speci®c questions regarding the ERSPC. 10±14 The questionnaires were to be self-completed. In both refusers and attenders, the following topics were examined: motives for (not) attending, knowledge of prostate cancer, attitude towards screening, and background characteristics (age, marital status, educational level, employment status, general health perception, urological complaints). The questionnaire also contained items regarding health-related quality of life, reported elsewhere.
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Knowledge of prostate cancer was examined with four statements, three of which were mentioned in the information lea¯et. The internal consistency, with only four items, was reasonable (for refusers and attenders, respectively, Cronbach's a = 0.53 and 0.59). Therefore, the sumscore was regarded as representing a knowledge dimension. The sumscore was calculated as the sum of correct minus incorrect answers, when all four items of the scale were completed (n = 208/226, 92 per cent; and n = 605/624, 97 per cent of completed scales). Attitudes towards population-based screening for prostate cancer were examined with three statements. Internal consistency for these three statements was low (Cronbach's a = 0.29 and 0.48); hence, these statements were viewed separately. To assess urological complaints, the Dutch-language version of the American Urological Association symptom index (AUA7) was used. 15 Standard statistical methods were applied using SPSS 6.1 for Windows (x 2 test, t-test, Mann±Whitney U-test, Cronbach's a).
Results
Uptake of screening and response to the questionnaires
From 1993 to 1997, uptake of screening remained at a sustained 42 per cent. The response rate to the questionnaires for refusers was 48 per cent (229/478; out of 500, 10 men had died and 12 had moved); the response rate for attenders was 99 per cent (624/626).
Motives for refusing or attending (Table 1) The main motives reported for refusing were absence of urological complaints and anticipated pain or discomfort, either as a single motive or in combination (10 per cent). A substantial proportion of men were under urological surveillance or did not attend for various logistic reasons. The main motives reported for attending were expected personal bene®t and the wish to make a contribution to science, either as a single motive or in combination (22 per cent). The presence of urological complaints was frequently mentioned as an important reason.
Knowledge and attitudes (Table 2) All knowledge statements were less often scored correctly by refusers compared with attenders. Differences of 10 per cent or more were found for the ®rst, third and fourth statement. The situation of more answers correct than wrong was found in 41 per cent of refusers, compared with 56 per cent in attenders (p < 0.001). The situation of all answers correct was found in 8 per cent of refusers, compared with 21 per cent of attenders (p < 0.001).
Differences were found in all three statements on attitudes towards population-based prostate cancer screening. Compared with refusers, attenders more often disagreed with the ®rst and the third statement, whereas attenders more often agreed with the second statement. In short, refusers compared with attenders had less knowledge about prostate cancer and a less positive attitude towards screening.
Background characteristics (Table 3) Compared with attenders, refusers were older, less often married and had a lower general health perception. Their educational level was lower and they tended to have paid work less often (p < 0.10), indicating a lower socioeconomic position.
Compared with attenders, refusers had a lower score on the AUA7, representing fewer symptoms; they also scored lower on each individual question (data not in the table). With regard to symptom-related quality of life, refusers scored higher than attenders.
Discussion
In this study we explored motives for refusing or attending population-based prostate cancer screening, by comparing questionnaire data from refusers and attenders of the sixth programme of the European Randomized Study of Screening for Prostate Cancer (ERSPC), in 1995±1996. A random sample of 500 refusers and 626 consecutive attenders received a questionnaire, which 48 per cent of refusers and 99 per cent of attenders returned. In relation to (non) attendance, we determined several background characteristics.
Main motives for refusing were absence of urological complaints and anticipated pain or discomfort. The motives for attending were expected personal bene®t, the wish to make a contribution to science, and urological complaints. Compared with attenders, refusers were signi®cantly older, less often married and worse educated with lower paid work (indicating a lower socioeconomic position); they had less knowledge about prostate cancer and a less positive attitude towards screening; they also had worse general health perception, but fewer urological complaints as determined by the AUA7.
Because the response to the questionnaires was almost complete in attenders (99 per cent), whereas the response in refusers was 48 per cent, selection in answering may have occurred. It can be speculated that non-responding refusers differ more from attenders with regard to knowledge, attitudes and sociodemographic characteristics than responding refusers; the differences are expected to be larger than reported here. Notably, the main reason mentioned for refusing, absence of urological complaints, could be different (lower prevalence) for refusers who did not respond to the questionnaire, compared with those who did.
The differences in sociodemographic characteristics, knowledge, attitudes, general health perception and motives in refusers versus attenders were consistent with evaluations on national screening programmes for women, such as cervical and breast cancer, and with recent ®ndings regarding prostate cancer screening.
12±14,16±18 The differences we found point to a role of socioeconomic position and prior knowledge and attitudes. We recommend that in designing strategies for approaching the general population, known health promotional aspects should carefully be considered. In particular, the role of urological complaints should be underlined.
The issue of urological complaints deserves further attention. In refusers, absence of urological complaints was the major reason for not attending (57 per cent); refusers had indeed, compared with attenders, lower scores ± that is, fewer urological complaints ± and better symptom-related quality of life on the AUA7. In contrast, a quarter of the attenders mentioned the presence of urological complaints as the major reason for attending. These ®ndings underline the need for good health education. An earlier evaluation showed that the information lea¯et for this screening program is adequate. 8 Apparently, the message`in absence of symptoms, attend the screening' is dif®cult to communicate, as was also found in a study comparing knowledge in African-American and Caucasian men. 18 An earlier evaluation of the ®rst ERSPC-pilot in 1992±1993 showed similar ®ndings to those in the present study with regard to knowledge about prostate cancer, attitudes towards population-based screening, and sociodemographic characteristics. 8 However, the study of 1992±1993 was conducted in an early stage of the trial, whereas in 1995±1996 the ERSPC trial had been operational for several years, and had become implemented over the entire city. We assume that in the mean time verbal communication had taken place. The screening policy had changed also. In 1992±1993 every participant in the screening and the control group received a pre-screening with PSA, after which randomization was carried out between adjuvant screening with DRE and TRUS, versus no further screening. This contrasts with the complete randomization approach of later years. Moreover, all participants ± screening and control ± had to visit the screening centre during the pilot of 1992±1993, whereas in 1995±1996 randomization was carried out by mail. Finally, here we focus more on differences in knowledge about prostate cancer and attitudes towards screening, and in addition we provide data on urological complaints in relation to (non) attendance. The importance of the issue of urological complaints has been underlined by our ®ndings. Uptake of screening was 42 per cent in the past few years. Several logistic improvements are conceivable, apart from the aspects related to non-attendance as found in this study: ®rst, by using reminders for the initial screening invitiation, which is now under investigation; second, by using a non-response reply chart. Men who are under urological surveillance or who received screening by other means can indicate that the invitation for population-based screening is not relevant for them. This allows for the calculation of adjusted uptake rates as well as total population coverage with regard to prostate cancer. Finally, and because each research method has its own pros and cons, we recommend that further research in this area should explore in greater depth the underlying motives for refusal; for example, by using a qualitative approach with face-to-face interviews alongside a quantitative approach with questionnaires.
Population-based screening for prostate cancer is controversial.
19±21 It is our conviction that the best compromise is to carry out randomized screening trials that compare screening with no screening and that use prostate cancer mortality as the main outcome. 7 Such trials are in progress in Europe and the United States. Cost±utility analysis should be included in an integral evaluation, and also the public health perspective should be taken into account. 22 From the present study we conclude that in refusing or attending population-based prostate cancer screening, not only urological complaints but also beliefs, attitudes and sociodemographic factors all seem to play a role. Therefore, the approach of the general population should be carefully considered.
